
New phase 3 trial data reveals Dapirolizumab pegol significantly reduces disease activity and fatigue in systemic lupus erythematosus patients, promising improved treatment outcomes.
Professor Eric Morand, MD, PhD, is head of the School of Clinical Sciences at Monash Health, Monash University's largest clinical school, and a physician-scientist.
He specializes in the study of systemic lupus erythematosus. He is founder of the Monash Lupus Clinic, Australia's largest research-grounded clinic for patients with SLE, a founding member of the Australian Lupus Registry & Biobank, and Chair of the Asia-Pacific Lupus Collaboration. His clinical research focuses on improving endpoints for clinical research in lupus. His lab has studied the biology of glucocorticoids in rheumatic disease and lupus since 1996.
He is a clinical rheumatologist, and head of the Monash Health Rheumatology Unit, the largest in Australia.

Published: July 15th 2025 | Updated: